Drug Profile
AZD 9164
Alternative Names: AZD9164Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 29 Jun 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Sweden (Inhalation)
- 28 Jun 2010 AtraZeneca terminates phase I trial [NCT01016951] in Chronic obstructive pulmonary disease in Sweden as one of the stopping criterion was met
- 30 Jun 2009 Phase-II clinical trials in Chronic obstructive pulmonary disease in Sweden (Inhalation)